Study of Cognitive and Behavioural Biases in People With Idiopathic Environmental Intolerance (IEI) Versus Healthy Controls

NCT ID: NCT06800976

Last Updated: 2025-12-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

69 participants

Study Classification

OBSERVATIONAL

Study Start Date

2026-03-31

Study Completion Date

2029-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Symptoms that patients attribute to the environment when no environmental cause can be identified are known as "idiopathic environmental intolerance" (IEI). IEI is often associated with a major psychological and socio-professional impact. Specific diagnostic tools and evidence-based treatment programs are still lacking. As a result, IEI patients often feel left behind by physicians and public health policies.

A number of environmental agents are singled out by IEI sufferers, including chemicals (cleaning products, tobacco smoke), electromagnetic fields generated by cell phones and base stations, air conditioning and infrasound emitted by wind turbines. Patients hold one or more of these environmental agents responsible for a very wide range of chronic, non-specific physical symptoms such as diffuse pain, fatigue, dizziness, dyspnoea, hot flushes, nausea, tinnitus or palpitations, but also cognitive symptoms such as loss of memory or concentration. However, the medical examination of IEI patients shows no evidence of bodily dysfunction.

Furthermore, numerous exposure studies have shown that environmental agents did not alter the biological parameters of IEI patients, that patients could not reliably distinguish between real and fictitious exposures, and that they only presented symptoms when they thought the exposure was real, whether this was true or not. This suggests that IEI symptoms can be considered "functional", resulting from an alteration in the way the body is felt rather than from injury to the body itself. Recently, several authors including Lemogne and Pitron have proposed a cognitive model of body awareness and more specifically of functional physical symptoms.This model is part of a Bayesian understanding of brain function, which is increasingly seen as a process underlying all perceptual experiences.From this perspective, bodily experiences are the result of probabilistic calculations Two sources of information are integrated, weighted by their reliability (accuracy) with regard to the current context: the body's sensory signals on the one hand (i.e. peripheral nerve inputs) and "priors" about the body on the other (i.e. pre-existing information from previous bodily experiences, beliefs about the body, emotions, etc.). In functional physical symptoms, it has been suggested that priors override the body's sensory signals, thus skewing bodily perception.This would be the consequence of an imbalance between low-precision sensory signals on the one hand, and high-precision priors on the other.

In line with this model, Van den Bergh and Witthöft have proposed an understanding of IEI as arising from a nocebo effect.Here, we propose a research project with patients suffering from IEI to test and validate this Bayesian theoretical model of IEI, the main study C22-19, BELIEFS which is currently recruiting.

This ancillary study, C24-26 BELIEFS-VS, enables us to include a population of healthy volunteers whom we will compare with the IEI patients in the main C22-19 BELIEFS study.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In the main BELIEFS study (ClinicalTrials ID NCT05973214), we are investigating the efficacy of a dedicated CBT treatment program for people with IEI, and the evolution of cognitive biases before versus after the treatment program. The present BELIEFS-VS ancillary study aims to include a group of healthy volunteers in order to compare cognitive outcomes in people with IEI. This BELIEFS-VS ancillary study will enable us to better study the cognitive characteristics of IEI patients in comparison with non-affected individuals, and thus gain a better understanding of the pathophysiology of the condition.

Methods and Analysis:

This is an observational study. Healthy controls will be age- and gender-matched to IEI patients. The healthy controls will be invited to one in-person session in our facilities, where they will be asked to fill in some questionnaires and complete some tasks (the Affective Picture Paradigm and the Belief Updating Task).

Ethics and dissemination:

Ethics approval has been granted. Results from this study will be published in peer-reviewed journals and presented at international conferences.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteers Idiopathic Environmental Intolerance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy

Healthy participants with no idiopathic environmental intolerance

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years of age or older; not suffering from an idiopathic environmental intolerance; informed consent is given.

Exclusion Criteria

* Suffering from a current psychiatric or neurological condition
* not being fluent in spoken and written French
* person subject to a period of exclusion for other research
* being imprisoned/jailed
* being hospitalized
* Persons of legal age who are subject to a legal protection measure (e.g. conservatorship, guardianship), persons of legal age who are unable to express their consent and who are not subject to a protection measure.
* being pregnant or breast-feeding

Translated with DeepL.com (free version)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Cédric Lemogne, Dr.

Role: PRINCIPAL_INVESTIGATOR

APHP Hôtel-Dieu

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Unité de pathologies professionnelles et environnementales, Hôtel-Dieu

Paris, Île-de-France Region, France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Victor Pitron, Dr.

Role: CONTACT

+33142348608

Tara M Petzke, Dr.

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Victor Pitron, Dr.

Role: primary

+33142348608

Tara M. Petzke, Dr.

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

C24-26

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Single-Component CBT for GAD
NCT02552108 COMPLETED NA